Concepedia

Andrae Lavon Vandross

AL

Statistics

Publications

4

Citations

116

H-Index

4

Active since

2022

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Texas Oncology

Massachusetts General Hospital

Cytel (United States)

Dana-Farber Cancer Institute

Andrae Lavon Vandross is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, targeted cancer therapy, and medicine.

Publications per year

2022–2023

4

Publications

4

First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a <i>TP53</i> Y220C mutation.

Ecaterina E. Dumbrava, Melissa L. Johnson, Anthony W. Tolcher et al. · Journal of Clinical Oncology · 2022 · 81 citations

, , +9

First-in-human dose-escalation study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with non-small cell lung, pancreatic, or colorectal cancer.

Anthony W. Tolcher, Alexander I. Spira, John Nemunaitis et al. · Journal of Clinical Oncology · 2023 · 13 citations

, , +17

A phase 1/2 study of DCC-3116 as a single agent and in combination with trametinib in patients with advanced or metastatic solid tumors with RAS or RAF mutations.

Anthony W. Tolcher, David S. Hong, Andrae Lavon Vandross et al. · Journal of Clinical Oncology · 2022 · 12 citations

, , +17

Abstract LB_A25: Updated Phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a <i>TP53</i> <i>Y220C</i> mutation

Alison M. Schram, Geoffrey I. Shapiro, Melissa L. Johnson et al. · Molecular Cancer Therapeutics · 2023 · 10 citations

, , +10

1–4 of 4